Jack Higgins - 01 Dec 2023 Form 4 Insider Report for Immunome Inc. (IMNM)

Role: Chief Scientific Officer
Signature: /s/ Sandra Stoneman, Attorney-in-fact
Issuer symbol: IMNM
Transactions as of: 01 Dec 2023
Net transactions value: $0
Form type: 4
Filing time: 05 Dec 2023, 21:08:56 UTC
Previous filing: 12 Oct 2023
Next filing: 13 Aug 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMNM	Stock option (right to buy)	Award	$0	+200,000		$0.000000	200,000	01 Dec 2023	Common Stock	200,000	$7.80	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 1, 2023, Dr. Higgins was granted an option to purchase 200,000 shares of common stock. The option vests (i) with respect to 100,000 shares, 25% of such shares subject to the option, vest on November 17, 2024, and the remaining shares will vest monthly thereafter over three years, and (ii) with respect to the remaining 100,000 shares, which vesting shall commence as of the date a certain condition set forth in Dr. Higgins' Amended and Restated Offer Letter dated November 30, 2023, is satisfied, 25% of the shares subject to the option will vest 1 year from the completion of that certain condition, and the remaining shares will vest monthly thereafter over three years.

Content

On December 1, 2023, Dr. Higgins was granted an option to purchase 200,000 shares of common stock. The option vests (i) with respect to 100,000 shares, 25% of such shares subject to the option, vest on November 17, 2024, and the remaining shares will vest monthly thereafter over three years, and (ii) with respect to the remaining 100,000 shares, which vesting shall commence as of the date a certain condition set forth in Dr. Higgins' Amended and Restated Offer Letter dated November 30, 2023, is satisfied, 25% of the shares subject to the option will vest 1 year from the completion of that certain condition, and the remaining shares will vest monthly thereafter over three years.